Some EpiPen auto-injectors recalled due to possible defect

Mylan is recalling select lots of EpiPen due to a defect that might render it difficult to activate in an emergency.
Mylan is recalling select lots of EpiPen due to a defect that might render it difficult to activate in an emergency.

(HealthDay News) — Mylan, the maker of EpiPen, says it is recalling select lots of EpiPen and EpiPen Jr. due to a defect that might render it difficult to activate in an emergency.

Mylan said the recall was prompted by 2 reports — both occurring outside the United States — of the products' failure to activate because of a potential defect in a component part.

"The incidence of the defect is extremely rare, and testing and analysis across the potentially impacted lots has not identified any units with a defect," the company said in a news release. "However, the recall is being expanded to include additional lots as a precautionary measure out of an abundance of caution. The recall impacts the 0.3 mg and 0.15 mg strengths of EpiPen Auto-Injector. None of the recalled lots include the authorized generic for EpiPen Auto-Injector."

Consumers can get a detailed list of EpiPen and EpiPen Jr. lots under recall by going to the company's website at mylan.com. They can also call Mylan at 877-796-9526. Consumers can receive a replacement of the recalled devices for free by calling 877-650-3494.

Meridian Medical Technologies, a Pfizer company, is Mylan's manufacturing partner for EpiPen Auto-Injector.

Reference

  1. Update on Meridian's Voluntary Worldwide Recall of EpiPen Auto-Injector. Mylan. Updated April 3, 2017. Accessed April 4, 2017.
You must be a registered member of Clinical Advisor to post a comment.
close

Next Article in Allergy and Immunology Information Center

Sign Up for Free e-newsletters